Abstract
Background
The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster (Dm‐dNK) was investigated for its broader substrate specificity and higher catalytic rate as a suicide gene in a combined gene/chemotherapy of cancer.
Methods
To evaluate the effects of nucleoside analog phosphorylation by Dm‐dNK in vitro and in vivo, we generated a replication‐deficient retroviral vector expressing Dm‐dNK to transduce human breast cancer cells MCF7 (ER+) and MDA‐MB‐231 (ER–). We further determined the enzymatic activity and the sensitivity of the nontransduced and Dm‐dNK‐transduced 231/dNK and MCF7/dNK cells to the pyrimidine nucleoside analogs araC and araT.
Results
The data obtained show that Dm‐dNK is enzymatically active and its overexpression in the nuclei of breast cancer cells results in an increased sensitivity to the nucleoside analogs araC and araT in vitro. Furthermore, subcutaneously transplanted 231/dNK cells were significantly inhibited after araC treatment, whereas nontransduced cancer cells continued to grow and develop in vivo.
Conclusions
These results suggest that the Dm‐dNK/nucleoside analog system could be a novel therapeutic strategy for treating breast cancer and improving anti‐tumor efficacy, as well as for optimizing approaches for suicide gene therapy. Copyright © 2011 John Wiley & Sons, Ltd.